Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04170426
Other study ID # CTX0019-001
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 2023
Est. completion date December 2026

Study information

Verified date April 2023
Source Celltex Therapeutics Corporation
Contact Jane Young
Phone 7135901000
Email jyoung@celltexbank.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigational new drug clinical trial for combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using intravenous injection of autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients. All subjects are monitored for safety (adverse events/severe adverse events) and evaluated for RAPID3, DAS28 and ACR20 regarding AdMSCs up to 52 weeks study duration.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 54
Est. completion date December 2026
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Must pass communicable disease screen tests for HIV, syphilis, Hepatitis B and C Consistent with American Rheumatism Association-European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis classification criteria - Active Rheumatoid Arthritis, see RA functional status of class I-IV - Patients must meet at least one of the following: > 6 swollen joints and = 6 involved joints (tenderness, swelling, deformity, pain on motion, or decreased motion) and morning stiffness = 45 minutes based on 68 joint count. - Patients must also meet at least one of the following: rheumatoid factor (RF) > 15 IU/mL or > 1:16, C-reactive protein (CRP) > 2.0 mg/dL, Erythrocyte Sedimentation Rate (ESR) > 30 mm/hour, and anti-cyclic citrullinated protein (Anti-CCP) > 20 U/mL, TNFa > 2.8 pg/mL. - Patients must have failed anti-rheumatoid drug due to adverse event or inefficacy for at least 12 week and at least 4 weeks on stable dose of methotrexate = 25 mg/week, or leflunomide = 20 mg/day, or sulfasalazine = 3 g/day, or steroids (Prednisone <10 mg/day). - For other medications, patients must be on the stable dose for at least 4 weeks prior to study entry in order to preclude changes to patient medication while participating on the study to ensure that a medication change could become a confounding factor in data interpretation. - All patients must be clinically stable with no significant changes in health status a minimum of at least 4 weeks prior to randomization and confirming patient eligibility Exclusion Criteria: 1. Current or prior to treatment - Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start - Evidence of immune suppression related to prior/current therapy - > 10% change in delivered monthly dose of anti-rheumatoid medications within 4 weeks prior to this stem cell infusion - Use of a new or additional anti-rheumatoid medication within 6 weeks prior to this stem cell infusion - Use of other stem cell therapy within 12 weeks prior to this stem cell therapy - Unwillingness or inability to comply with study procedures 2. Concurrent Conditions - Clinically active malignant disease - Severe bladder or thrombotic disorder - History of known pulmonary embolism or known secondary anti-phospholipid syndrome - Known or suspected hypersensitivity to any components used to culture or store the AdMSCs, e.g. sulfur or sulfonamide - Known or suspected antibodies to any components used to culture the AdMSCs, e.g. BSA and sulfur containing products (e.g., DMSO) - Active infection at time of planned study treatment start - Age related pathology likely to inhibit study participation or completion - Major trauma or surgery within 14 days of study treatment start - Mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study - Alcohol, drug, or medication abuse within one year before study treatment start - Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study - Irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure - Heavy smokers, bed-bound patients, patients or family history with hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc. 3. Laboratory Parameters - Hepatic impairment, defined as any of ALT, AST, LDH or bilirubin > 2 x the upper limit of normal (ULN) range according to local laboratory standards - Renal impairment, defined as serum creatinine > 133 mmol/L (1.5 mg/dL) - Positive virology/serology for human immunodeficiency virus (HIV), hepatitis B (HBsAg positive), hepatitis C and/or syphilis 4. Pregnancy / contraception - Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
autologous adipose derived stem cells
Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Celltex Therapeutics Corporation

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events and Sever Adverse Events The total number of adverse events and severe adverse events related and non-related with AdMSCs will be recorded to indicate the safety and tolerability. 52 weeks
Secondary Efficacy of Celltex AdMSCs Proportion of ACR 20 patients (swollen joints, tender joints, patient assessment of pain, RAPID3, DAS28-CRP and blood inflammatory panel tests) in comparison between baseline and post-treatment follow-up data. 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4